RPPA Protein Profiling Services | NMI TT Pharmaservices

home contact company.overview news sitemap print

Protein Profiling

Contact

NMI-TT Contact Person

Dr. Michael Pawlak

+49 7121 51530 13


Download Flyer






RPPA Protein/Pathway Profiling Services

  • Preclinical profiling of lead compound candidates
  • Clinical testing based on an established QM system
  • Investigation & evaluation of compound modes of action
Reverse Phase Protein Arrays (RPPAs) are planar arrays of printed cell and tissue lysates. Using RPPAs, changes of protein levels and their activation status (e.g. phospho-signaling) can be detected in numerous cell and tissue sources, e.g. cancer. The miniaturized array and direct immunoassay format (based on the Zeptosens platform) enable efficient and comprehensive analyses of cellular signaling networks for hundreds of proteins and samples in parallel with low sample consumption.

    Key features
  • Established technology, with proven added value
  • ISO9001 compliant, robust Standard Operating Procedures (SOPs)
  • More than 10 years of experience in designing and performing RPPA studies for life science industry and academic research
  • For studies of 30 up to hundreds of samples
  • Select analytes from our list of 382 pre-validated pathway marker antibodies for total proteins and post-translationally modified forms
  • Additional antibodies for signaling proteins of interest can be validated upon request

    Established applications
  • Lead compound mechanism-of-action and translational studies
  • Quantification of on/off target & downstream signaling effects
  • Transient selective pathway inhibition and cross-pathway effects
  • Biomarker screening/verification of preclinical & clinical samples
  • Mechanisms and markers for treatment efficacy and resistance
  • Providing rationale for treatment combination strategies to overcome resistance mechanisms

    Typical samples
  • Cell cultures (2D; 3D, e.g. spheroids, microtissues)
  • Animal tissues (different organs)
  • Xenografts, PDX tumor models
  • Patient tissues, tumor biopsies, either fresh frozen (FF) or formalin-fixed paraffin-embedded (FFPE)
  • Minimum sample amount required for a typical RPPA study: 30 µg total protein at 3 µg/µl protein concentration
Please download our RPPA flyer, or email us to get a quote.



References

Pawlak et al. (2002) Proteomics
Saturno et al. (2007) Toxicologic Pathology
Pirnia et al. (2009) Proteomics
Assadi et al. (2013) Mol Cell Proteomics
Akbani et al. (2014) Mol Cell Proteomics
Tegnebratt et al. (2014) EJNMMI Research
Bader et al. (2015) Mol Cell Proteomics

 

Linked in profile

NMI TT is a subsidiary of NMI